A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Docetaxel (Primary) ; Sirexatamab (Primary)
- Indications Adenocarcinoma; Carcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 11 Jul 2022 Planned End Date changed from 1 Dec 2022 to 31 Aug 2023.
- 11 Jul 2022 Status changed from recruiting to active, no longer recruiting.